A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.

Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone-sensitive prostate cancer (mHSPC).